The choice between weight loss medications has just become simpler. As of April 2026, two oral GLP-1 drugs are now available in the U.S.: Wegovy, the pill version of Novo Nordisk’s injectable semaglutide, and Foundayo, Lilly’s first small-molecule GLP-1 agonist, orforglipron. Both provide needle-free options for adults with obesity or overweight conditions, though their mechanisms, convenience, and real-world outcomes differ significantly.
Two drugs, two distinct mechanisms
Wegovy, already known as an injectable, is now available as a daily oral pill. It functions by imitating GLP-1, a hormone that suppresses appetite and slows digestion. Users must take it first thing in the morning on an empty stomach, with no more than four ounces of water, and wait 30 minutes before eating, drinking, or taking other medications. These requirements reflect the difficulty of delivering peptide-based drugs like semaglutide through the digestive system.
Foundayo, developed by Lilly, uses a different chemical approach. It is a small-molecule GLP-1 agonist designed to endure stomach acid without requiring fasting or timing restrictions. “Orforglipron’s small molecule structure lets it pass through the gut intact regardless of what you’ve eaten or when,” Dr. Yang says. “No fasting window, no timing your coffee. You just take it.”
This difference extends beyond convenience. While peptide-based GLP-1 drugs like semaglutide have dominated the market, small-molecule versions have been explored for years as a way to avoid the limitations of injections or strict dosing schedules. Foundayo’s approval represents the first time such a drug has been approved specifically for weight loss, though similar chemistry has been used in diabetes treatments for some time.
Weight loss outcomes: comparable but not identical
Both medications produce significant weight loss, but the results vary. In Lilly’s clinical trials, adults taking the highest dose of Foundayo lost an average of 27 pounds (12.4% of body weight) over 72 weeks. Wegovy’s trial data shows slightly higher outcomes: 33 pounds (14% of body weight) over 64 weeks. However, these figures require careful interpretation.
Novo Nordisk published an indirect comparison in April 2026, suggesting its 25-milligram Wegovy pill outperformed 36-milligram Foundayo—a dose not yet cleared for commercial use by the FDA. The company noted that Wegovy users lost more weight and that Foundayo users were four times more likely to discontinue treatment due to side effects. Lilly countered that indirect comparisons cannot replace direct head-to-head trials. A spokesperson for Lilly argued that Foundayo’s ease of use—no food or water restrictions—may improve adherence, which often outweighs minor differences in weight loss.
Medical professionals agree the distinction between the two is not drastic. “At the end of the day, both will help you lose weight and the amount of weight loss between the two is very similar,” Dr. Yang adds. The greater factor may be patient behavior rather than the drug itself. “Patients still have to make the right choices, including eating the right foods,” Dr. Yang says.
The primary trade-off lies in how each drug is taken. Wegovy’s strict dosing rules may suit those who prefer structure, while Foundayo’s flexibility could transform outcomes for shift workers, frequent travelers, or anyone struggling with consistency. Research consistently shows that the best medication is the one you’ll actually take consistently. Ultimately, this comes down to an honest conversation with your health care provider about your goal.
Side effects: overlapping but not the same
Both drugs share common side effects, including nausea, constipation, diarrhea, and fatigue. However, Foundayo adds hair loss, indigestion, and abdominal swelling to its profile, while Wegovy includes dizziness, low blood sugar (for diabetics), and gastroenteritis. The similarities suggest digestive discomfort will persist across GLP-1 drugs, but the variations indicate how chemical structure affects tolerability.
Novo Nordisk’s indirect analysis also highlighted a critical real-world issue: patient dropout rates. If side effects lead to early discontinuation, the drug’s effectiveness diminishes. Foundayo’s smaller molecule may offer an advantage here, but without direct comparisons, the full impact remains unclear.
The choice between Wegovy and Foundayo also depends on how each interacts with other medications. Wegovy’s strict dosing, taken first thing in the morning with no food or water, creates a narrow window for potential drug interactions. Patients on blood pressure medications, diabetes treatments, or other oral drugs may find coordinating doses difficult. The 30-minute wait before consuming anything else further complicates this, particularly for those managing multiple daily medications. Physicians emphasize that timing is critical not only for absorption but also to reduce the risk of semaglutide interfering with other drugs as they pass through the digestive system.
Foundayo eliminates these concerns entirely. Its small-molecule structure means no fasting or timing adjustments are needed, reducing the risk of missed doses or interactions with other oral medications. This flexibility is especially valuable for patients with complex medication regimens, such as those with chronic conditions like hypertension or diabetes. However, the drug’s broader chemical profile may introduce new considerations. Lilly’s clinical data suggests Foundayo’s metabolism differs slightly from peptide-based GLP-1s, potentially affecting how it interacts with certain liver enzymes. While no major warnings have emerged, prescribers may need to monitor patients more closely if they are taking drugs metabolized by the same pathways, such as some antidepressants or immunosuppressants.
Long-term planning for patients
Patients beginning either drug should prepare for gradual dose adjustments, as both require a stepped approach to minimize side effects. Wegovy’s oral formulation follows the same titration schedule as its injectable version, starting at 0.24 mg weekly and increasing to 2.4 mg over 16 weeks. Foundayo’s dosing begins at 7.2 mg daily, escalating to 17.2 mg over eight weeks. Physicians note that slower dose increases generally improve tolerability, particularly for nausea and digestive discomfort. However, the oral route may allow for slightly faster adjustments in some cases, as patients can more easily skip a dose if needed without the permanence of an injection.
